

**Editor**

Leo van de Putte (The Netherlands)

**Associate Editors**

Thomas Bardin (France)  
Johannes Bijlsma (The Netherlands)  
Gerd Burmester (Germany)

Bevrah Hahn (USA)  
Frank Wollheim (Sweden)  
Anthony Woolf (UK)

**Methodological Adviser**

Jaap Fransen (The Netherlands)

**Editorial Board**

M Aringer (Austria)  
P Bacon (UK)  
F Berenbaum (France)  
M Boers (The Netherlands)  
D Boumpas (Greece)  
B Bresnihan (Ireland)  
H Capell (UK)  
M Cutolo (Italy)  
G Firestein (USA)  
P Goupille (France)  
E Gravalles (USA)  
W Gross (Germany)  
F Guillemin (France)  
G Herrero-Beaumont (Spain)  
F Houssiau (Belgium)  
T Huizinga (The Netherlands)  
C Jorgensen (France)  
G Kollias (Greece)  
T Kvien (Norway)  
M Leirisalo-Repo (Finland)  
F Luijten (Belgium)  
H-M Lorenz (Germany)  
W Maslinski (Poland)  
M Maticci Cerinic (Italy)

K Nishioka (Japan)  
M Nurmohamed (The Netherlands)  
S Özen (Turkey)  
T Pap (Germany)  
E Pascual Gómez (Spain)  
L Punzi (Italy)  
L Rönblom (Sweden)  
B Rozman (Slovenia)  
G Schett (Austria)  
J Da Silva (Portugal)  
H Schulze-Koops (Germany)  
A So (Switzerland)  
T Sokka (USA)  
D Symmons (UK)  
P-P Tak (The Netherlands)  
A Tyndall (Switzerland)  
A Tzioufas (Greece)  
J Vencovsky (Czech Republic)  
M Ward (USA)  
M Weisman (USA)  
H Yazici (Turkey)  
Editor, *BMJ*

**Advisory Committee**

W vd Berg (The Netherlands)  
S Bombardieri (Italy)  
F Breedveld (The Netherlands)  
L Crofford (USA)  
J-M Dayer (Switzerland)  
M Doherty (UK)  
M Dougados (France)  
J Edmonds (Australia)  
P Emery (UK)  
D Furst (USA)  
S Gay (Switzerland)  
J Kalden (Germany)  
E Keystone (Canada)  
L Klareskog (Sweden)

P Lipsky (USA)  
S Lohmander (Finland)  
R Maini (UK)  
E M Mola (Spain)  
H Moutsopoulos (Greece)  
J O'Dell (USA)  
K Pavelka (Czech Republic)  
J Rovinsky (Slovakia)  
Y Shoenfeld (Israel)  
J Smolen (Austria)  
W van Venrooy (The Netherlands)  
E Veys (Belgium)  
A Wiik (Denmark)

**Guidelines for Authors and Reviewers**

Guidance for authors and reviewers can be found at <http://ard.bmj.com/fora>  
All papers must be submitted via Bench>Press at <http://submit-ard.bmj.com>

**Disclaimer**

*Annals of the Rheumatic Diseases* is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.

The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

The *Annals of the Rheumatic Diseases* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of the *Annals of the Rheumatic Diseases* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Subscription Information**

See p iv  
ISSN 0003-4967 (print); 1468-2060 (online)


**Copyright**

© 2007 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

• Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at <http://annrheumdis.com/fora/licence.dtl>

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, copyedited by Macmillan India Ltd, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Cambrian Printers Limited, Aberystwyth

• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



In the later stages of the immune response, anti-inflammatory cytokines such as IL4 and IL13 are released to reduce the inflammatory response. See p992

**Editorial**

989 Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?  
*S G O'Neill, D A Isenberg, A Rahman*

**Extended reports**

992 Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis  
*J G Walker, M J Ahern, M Coleman, H Weedon, V Papangelis, D Beroukas, P J Roberts-Thomson, M D Smith*

1000 Anti-β<sub>2</sub>GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome  
*C Hamid, K Norgate, D P D'Cruz, M A Khamashta, M Arno, J D Pearson, G Frampton, J J Murphy*

1008 Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients  
*T C T M van der Pijl, C Kraan, C A Wijbrandts, L G M van Baarsen, A E Voskuyl, F Rustenburg, J M Baggen, S M Ibrahim, M Fero, B A C Dijkmans, P P Tak, C L Verweij*

1015 A Sonographic Enthesitic Index of lower limbs is a valuable tool in the assessment of ankylosing spondylitis  
*M Alcalde, J C Acebes, M Cruz, L González-Hombrado, G Herrero-Beaumont, O Sánchez-Pernaute*

1020 Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis  
*H Wittkowski, D Foell, E af Klint, L De Rycke, F De Keyser, M Frosch, A-K Ulfgren, J Roth*

1026 Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study  
*J M van Woerkom, A A Kruize, R Geenen, E N van Roon, R Goldschmeding, S M M Verstappen, J A G van Roon, J W J Bijlsma*

1033 Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage  
*J K de Vries-Bouwstra, Y P M Goekoop-Ruiterman, J Wesoly, H J Hulsmans, A J M de Craen, F C Breedveld, B A C Dijkmans, C F Allaart, T W J Huizinga*

1038 The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study  
*M S Heiberg, C Kaufmann, E Rødevand, K Mikkelsen, W Koldingsnes, P Mowinckel, T K Kvien*

1043 Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by



[www.publicationethics.org.uk](http://www.publicationethics.org.uk)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

Ann Rheum Dis: first published as on 1 August 2007. Downloaded from <http://ard.bmj.com/> on May 28, 2024 by guest. Protected by copyright.

- TNF  $\alpha$  in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis  
*E Kunisch, M Gandesiri, R Fuhrmann, A Roth, R Winter, R W Kinne*
- 1052 Further evidence of the role of frizzled-related protein gene polymorphisms in osteoarthritis  
*J Rodriguez-Lopez, M Pombo-Suarez, M Liz, JJ Gomez-Reino, A Gonzalez*
- 1056 Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout  
*E Pascual, F Sivera*
- 1059 Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study  
*M Schoels, T Kapral, T Stamm, J S Smolen, D Aletaha*
- 1066 Cigarette smoking and radiographic progression in rheumatoid arthritis  
*A Finckh, S Dehler, K H Costenbader, C Gabay, on behalf of the Swiss Clinical Quality Management project for RA (SCQM)*
- 1072 The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice  
*B Vander Cruyssen, C Ribbens, A Boonen, H Mielants, K de Vlam, J Lenaerts, S Steinfeld, F Van den Bosch, L Dewulf, N Vastesaeger*
- 1078 Reliability of the ICF Core Set for rheumatoid arthritis  
*T Uhlig, S Lillemo, R H Moe, T Stamm, A Cieza, A Boonen, P Mowinckel, T K Kvien, G Stucki*
- 1085 Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals  
*É Biró, R Nieuwland, P P Tak, L M Pronk, M C L Schaap, A Sturk, C E Hack*
- 1093 Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis  
*H B Hammer, S Ødegaard, M K Fagerhol, R Landewé, D van der Heijde, T Uhlig, P Mowinckel, T K Kvien*
- 1098 Validation of the ABILHAND questionnaire as a measure of manual ability in patients with rheumatoid arthritis  
*P Durez, V Fraselle, F Houssiau, J-L Thonnard, H Nielens, M Penta*

## Concise reports

- 1106 In vivo evidence for apoptosis in the bone marrow in systemic lupus erythematosus  
*A L Hepburn, I A Lampert, J J Boyle, D Horncastle, W F Ng, M Layton, T J Vyse, M Botto, J C Mason*
- 1110 The intra-articular distribution of  $^{90}\text{Y}$ trium does not influence the clinical outcome of radiation synovectomy of the knee  
*Z N Jahangier, F M van der Zant, J W G Jacobs, H G Riedstra, G M M Gommans, J F Verzijlbergen, J W J Bijlsma, J W van Isselt*
- 1113 The *TNFRSF1A R92Q* mutation is frequent in rheumatoid arthritis but shows no evidence for association or linkage with the disease  
*P Dieudé, M Goossens, F Cornélis, L Michou, T Bardin, Dimitri Olegovitch Tchernitchko for the European Consortium on Rheumatoid Arthritis Families*
- 1116 Genetic susceptibility to total hip arthroplasty failure: a preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor  
*M H A Malik, F Jury, A Bayat, W E R Ollier, P R Kay*

## Letters

- 1121 New markers and an old phenomenon: prozone effect disturbing detection of filaggrin (keratin) autoantibodies  
*F Dubois-Galopin, C Beauvillain, D Dubois, A Pillet, G Renier, P Jeannin, C Masson, A Chevaillier*
- 1122 Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis  
*E P K Yu, A J K Ostor, F C Hall*
- 1124 Increased sensitivity to extracellular ATP of fibroblasts from patients affected by systemic sclerosis  
*A Lo Monaco, S Gulinelli, G Castellino, A Solini, D Ferrari, R La Corte, F Trotta, F Di Virgilio*
- 1125 In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment  
*O R Baricordi, M Govoni, R Rizzo, F Trotta*
- 1126 A "new" technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography  
*G Filippou, B Frediani, A Gallo, L Menza, P Falsetti, F Baldi, C Acciai, S Lorenzini, M Galeazzi, R Marcolongo*
- 1128 Forthcoming events
- 1128 Correction